Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 11, Number 1—January 2005

Research

Hepatitis C Virus Infection, Linxian, China1

Mingdong Zhang*, Xiu-Di Sun†, Steven D. Mark*, Wen Chen†, Lara Wong*, Sanford M. Dawsey*, You-Lin Qiao†, Joseph F. Fraumeni*, Philip R. Taylor*, and Thomas R. O’Brien*Comments to Author 
Author affiliations: *National Institutes of Health, Bethesda, Maryland, USA; †Cancer Institute, Chinese Academy of Medical Sciences, Beijing, China

Main Article

Table

Prevalence of anti-HCV (by RIBA), HBsAg, and HBcAb in Linxian in 2000*

N (%) Anti-HCV % 
(95% CI) p HBcAb % 
(95% CI) p HBcAb and HBsAg % 
(95% CI) p
Overall 9.6 (7.0–12.2) 54.6 (50.2-59.0) 6.4 (4.3-8.5)
Age in 2000 (y)
<59 166 (33.2) 8.4 (4.2–12.7) 53.6 (46.0–61.2) 5.4 (2.0–8.9)
60–64 105 (21.0) 13.3 (6.8–19.8) 50.5 (40.9–60.0) 6.7 (1.9–11.4)
65–69 90 (18.0) 11.1 (4.6–17.6) 50.0 (39.7–60.3) 4.4 (0.2–8.7)
70–74 82 (16.4) 6.1 (0.9–11.3) 62.2 (51.7–72.7) 8.5 (2.5–14.6)
>75 57 (11.4) 8.8 (1.4–16.1) 0.50 61.4 (48.8–74.0) 0.34 8.8 (1.4–16.1) 0.73
Sex
Male 200 (40.0) 9.5 (5.4–13.6) 58.0 (51.2–64.8) 5.0 (2.0–8.0)
Female 300 (60.0) 9.7 (6.3–13.0) 0.95 52.3 (46.7–58.0) 0.21 7.3 (4.4–10.3) 0.18
Commune
Yaocun 170 (34.0) 11.8 (6.9–16.6) 53.5 (46.0–61.0) 6.5 (2.8–10.2)
Rencun 95 (19.0) 14.7 (7.6–21.9) 64.2 (54.6–73.8) 6.3 (1.4–11.2)
Donggang 116 (23.2) 2.6 (0.0–5.5) 53.5 (44.4–62.5) 6.0 (1.7–10.4)
Hengshui 119 (23.8) 9.2 (4.0–14.4) 0.02 49.6 (40.6–58.6) 0.18 6.7 (2.2–11.2) 0.50

*HCV, hepatitis C virus; RIBA, recombinant immunoblot assay; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; CI, confidence interval.

Main Article

1Presented in part at the 11th Triennial International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia, April 4–10, 2003.

TOP